Catalent Inc (0C8.BE)
| Previous close | 51.91 |
| Open | 51.79 |
| Bid | 51.73 x 0 |
| Ask | 51.94 x 0 |
| Day's range | 51.79 - 51.79 |
| 52-week range | 29.10 - 55.50 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Catalent, Inc. Reports Third Quarter Fiscal 2024 Results
SOMERSET, N.J., May 08, 2024--Catalent, Inc. (NYSE: CTLT) ("Catalent"), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the third quarter of fiscal 2024, which ended March 31, 2024.
- Business Wire
Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment
SOMERSET, N.J., March 07, 2024--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, has today published its fiscal 2023 Corporate Responsibility Report, highlighting positive progress across every pillar of Catalent’s corporate responsibility strategy – People, Environment, and Community. The report also outlines the company’s future commitments as it progresses its mission to help people lead better and healthier lives.
- Business Wire
Catalent, Inc. Reports Second Quarter Fiscal 2024 Results
SOMERSET, N.J., February 09, 2024--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the second quarter of fiscal 2024, which ended December 31, 2023.
